Competitive Rivalry

Lenz Therapeutics competes in the crowded ophthalmology and aesthetics-adjacent prescription market, where global peers with larger sales forces can pressure launch pricing and share.

Rivalry is intensified by established eye-care franchises from Alcon, Bausch + Lomb, and AbbVie/Allergan, which typically have broader formularies and stronger physician access than LENZ.

Because LENZ is earlier in commercialization and narrower in product scope than diversified peers, it has less ability to offset price competition with portfolio leverage.

Threat Of New Entrants

Regulatory approval, clinical evidence generation, and ophthalmology commercialization create meaningful barriers that limit rapid entry versus generic or small-cap development peers.

Specialty prescriber relationships and reimbursement access are difficult to replicate quickly, which supports incumbent pricing power relative to new entrants.

However, the category remains attractive to well-capitalized biopharma entrants, so barriers are real but not prohibitive over a 2–5 year horizon.

Bargaining Power Of Suppliers

LENZ depends on contract manufacturing, active ingredients, and specialized packaging, but these inputs are generally available from multiple qualified suppliers, limiting extreme supplier leverage.

Compared with large-cap peers that can dual-source at scale, LENZ likely faces somewhat higher unit-cost sensitivity and less procurement bargaining power.

Supplier power is moderated by the standardized nature of many ophthalmic inputs, but any concentration in sterile fill-finish capacity can still pressure margins.

Bargaining Power Of Buyers

Buyers include physicians, payers, and pharmacy channels, and reimbursement scrutiny can materially constrain net pricing versus peers with stronger formulary positions.

Large payers and PBMs can extract discounts from smaller ophthalmology launches, leaving LENZ with less pricing flexibility than diversified global eye-care companies.

Physician adoption can support premium positioning, but the ultimate buyer chain still limits realized net price more than it does for category leaders.

Threat Of Substitutes

Substitution risk comes from alternative therapies, watchful waiting, and competing ophthalmic treatments that can cap durable pricing power in the category.

Compared with peers in more differentiated specialty drugs, LENZ faces a meaningful risk that clinicians and payers can shift demand toward established alternatives.

The substitute threat is not overwhelming, but it keeps long-term margin expansion dependent on maintaining clear clinical differentiation versus existing standards of care.

Overall Score

LENZ operates in a structurally challenging but not prohibitive industry, with meaningful rivalry and buyer pressure offset by moderate entry barriers and manageable supplier risk.